CompletedPhase 2/3

Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction

United States50 participantsStarted 2010-09

Plain-language summary

The objective is to evaluate the feasibility of using additional screening methods to optimize effectiveness outcomes with the LipiFlow System for application of heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye, and chalazia. The screening methods include diagnostic expression of the meibomian glands and interferometry assessment of the tear film.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Meibomian gland dysfunction * Dry Eye symptoms Exclusion Criteria: * Ocular surgery, ocular injury or ocular Herpes infection within past 3 months * Active ocular infection * Active ocular inflammation or recurrent inflammation within past 3 months * Moderate to severe allergic conjunctivitis * Severe eyelid inflammation * Eyelid abnormalities that affect lid function * Ocular surface abnormalities that may compromise corneal integrity * Systemic disease conditions or medications that cause dry eye * Use of other treatments for meibomian gland dysfunction or dry eye * Pregnant or nursing women * Participation in another ophthalmic clinical trial within past 30 days

What they're measuring

Association Between Screening Methods (Meibomian Gland Expression) and Treatment Effectiveness Outcomes (Total Meibomian Gland Score)

Timeframe: Baseline and 4 Weeks

Trial details

NCT IDNCT01202747

SponsorTearScience, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2011-01

Results submitted2011-09-16

View on ClinicalTrials.gov More Chalazion trials